Page last updated: 2024-12-09

(4-bromo-2,5-dimethyl-3-pyrazolyl)-(2,3-dihydroindol-1-yl)methanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

(4-Bromo-2,5-dimethyl-3-pyrazolyl)-(2,3-dihydroindol-1-yl)methanone is a **synthetic compound** that is not commonly found in nature. It's a complex molecule with a specific structure, and its importance in research likely stems from its potential applications or unique properties.

Here's a breakdown of the molecule's structure and potential significance:

**Structure:**

* **Pyrazole ring:** The core of the molecule is a pyrazole ring. Pyrazoles are heterocyclic aromatic compounds, meaning they contain atoms other than carbon within the ring. They are commonly used in pharmaceuticals and agricultural chemicals.
* **Bromo substituent:** The molecule features a bromine atom attached to the pyrazole ring. This can significantly affect the molecule's reactivity and pharmacological properties.
* **Methyl substituents:** Two methyl groups are attached to the pyrazole ring. These small alkyl groups also influence the molecule's properties.
* **Dihydroindole ring:** The molecule is linked to a 2,3-dihydroindole ring. Dihydroindoles are a class of compounds often found in pharmaceuticals.
* **Ketone group:** A carbonyl group (C=O) connects the pyrazole and dihydroindole portions.

**Potential Research Significance:**

Based on its structure, this molecule could be significant for research in several areas:

* **Medicinal Chemistry:** The combination of a pyrazole ring, a dihydroindole ring, and the ketone group is commonly found in pharmaceuticals. The molecule could potentially be used as a lead compound in the development of new drugs.
* **Organic Chemistry:** The molecule could be used as a building block for synthesizing other complex molecules with novel properties.
* **Materials Science:** The molecule's unique structure might lead to interesting applications in materials science, for example, in the development of new organic materials or in the synthesis of polymers.

**To definitively understand the importance of this specific molecule, we need more information:**

* **Research context:** What is the specific research area or project where this molecule is being studied?
* **Properties:** What are the molecule's physical and chemical properties? For example, what is its solubility, melting point, and reactivity?
* **Biological activity:** Does the molecule exhibit any biological activity? This could include interactions with proteins, enzymes, or cells.

**Therefore, without additional information, it's difficult to provide a definitive answer about why this specific molecule is important for research.**

Cross-References

ID SourceID
PubMed CID844740
CHEMBL ID1504243
CHEBI ID119765

Synonyms (16)

Synonym
1-[(4-bromo-1,3-dimethyl-1h-pyrazol-5-yl)carbonyl]indoline
smr000228334
MLS000698064 ,
CHEBI:119765
AKOS003752688
(4-bromo-2,5-dimethylpyrazol-3-yl)-(2,3-dihydroindol-1-yl)methanone
HMS2550A23
CHEMBL1504243
STL394982
(4-bromo-1,3-dimethyl-1h-pyrazol-5-yl)(2,3-dihydro-1h-indol-1-yl)methanone
(4-bromanyl-2,5-dimethyl-pyrazol-3-yl)-(2,3-dihydroindol-1-yl)methanone
cid_844740
(4-bromo-2,5-dimethyl-3-pyrazolyl)-(2,3-dihydroindol-1-yl)methanone
bdbm69068
(4-bromo-2,5-dimethyl-pyrazol-3-yl)-indolin-1-yl-methanone
Q27207226
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
indolyl carboxylic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency9.20000.000811.382244.6684AID686978
chromobox protein homolog 1Homo sapiens (human)Potency31.62280.006026.168889.1251AID540317
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624296
lamin isoform A-delta10Homo sapiens (human)Potency14.12540.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glycogen synthase kinase-3 beta isoform 1Homo sapiens (human)EC50 (µMol)300.00000.212522.156283.9400AID434954
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]